Conventional endotracheal tubes
Conventional endotracheal tubes
FCV® can be applied via conventional endotracheal tubes (5-9 mm ID)
Controlling the inspiration and expiration phase
FCV® is unique in controlling the inspiration as well as the expiration phase during artificial ventilation of a patient. This is established by generating a continuous flow into the patient’s lungs followed by a continuous (negative) flow, sucking gasses out of the patient’s lungs. FCV results in linear increases and decreases in intratracheal pressures.
Conventional Tube Adapter (CTA)
FCV® needs a resistor in the respiratory circuit, to prevent any passive expiration and to enable to fully control both the inspiration and expiration. Therefore, Ventinova developed the Conventional Tube Adapter (CTA), which has a high resistant tubing. The pressure lumen of the CTA allows intratracheal pressure measurements at the distal part of the endotracheal tube, to which the CTA is connected. This ensures safe ventilation between set Peak and PEEP pressures.
Tritube: in case of a difficult airway or laryngeal surgery
In case of a (anticipated) difficult airway or laryngeal surgery, FCV® allows the use of the ultrathin and highly resistive Tritube instead of a conventional endotracheal tube with CTA.
The use of CTA with an conventional endotracheal tube or Tritube does not have an impact on the high ventilation efficiency or low energy related to FCV.
Evone in ICU
FCV® – as compared to conventional ventilation methods – has been shown to provide a more homogenous aeration of the lungs while reducing atelectasis, resulting in a higher ventilation efficiency and an improved lung function. Furthermore, the energy dissipation into the lungs has been suggested to be reduced during FCV®. Although published clinical data has been mostly obtained in an operating room (OR) setting and our experiences on the intensive care unit (ICU) are still limited, the present body of evidence suggests that the demonstrated advantages of FCV® can be equally transferred to an ICU setting. Especially severely ill ARDS patients are likely to benefit from a gentle, yet higher efficient ventilation strategy with minimized energy dissipation to avoid ventilator-induced lung injury and support recovery of the lungs. To date, the first observations on Covid-19 patients look promising.
We would like to work together with the field to gather more clinical evidence in an ICU setting.
Full respiratory control
Ventilation possible via conventional endotracheal tube and our ultrathin Tritube
Higher efficient ventilation with lung protective potential
latest news
COVID-19 Update
First COVID-19 ICU patients ventilated with Evone show promising results
First COVID-19 ICU patients ventilated with Evone show promising results
latest news
COVID-19 Update
OUR Mission:
Let’s redefine ventilation.
Together, we question, we create, we care, we educate, we celebrate
Patient ventilation with minimal impact and maximal control
We are VENTINOVA.
Please sign up for our press mailings
LATEST NEWS
Dutch Ministry of Health also opts for Evone® by Ventinova from Eindhoven
Dutch Ministry of Health also opts for Evone® by Ventinova from Eindhoven Results of FCV®-equipped ventilation equipment appears promising Eindhoven, 2 April 2020 – Ventinova Medical, a company based in Eindhoven, received good news today; this concerns...
SIGN UP FOR OUR NEWSLETTER:
CONTACT US
Ventinova Medical
Meerenakkerplein 7
5652 BJ Eindhoven (NL)
T. +31 (0)40 7516020
E. info@ventinova.nl
Chamber of Commerce: 58307834